Fairfield, Bush & Co’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-23
Closed -$498 393
2023
Q4
$498 Buy
+23
New +$475 ﹤0.01% 479
2023
Q3
Sell
-25
Closed -$522 409
2023
Q2
$522 Buy
+25
New +$503 ﹤0.01% 494

Other funds holding REVS

Fairfield, Bush & Co's REVS Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of Columbia Research Enhanced Value ETF (REVS) in Q1 2024, closing a stake of 23 shares — an estimated $498 sold.

Fairfield, Bush & Co first reported a position in REVS in Q2 2023 and held it in 2 quarters. The position peaked at $522 in Q2 2023. 16 funds tracked by Wall St. Rank hold REVS as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining Columbia Research Enhanced Value ETF position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 23 Columbia Research Enhanced Value ETF shares in Q1 2024, an estimated $498.
  • Fairfield, Bush & Co first reported a position in Columbia Research Enhanced Value ETF in Q2 2023 and held it in 2 quarters.
  • Fairfield, Bush & Co's Columbia Research Enhanced Value ETF position peaked at $522 in Q2 2023.
  • 16 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.